GlassScriptPhysician profile
Gary S Garcia
NPI 1417368788
$9,699.17
in general payments reported to CMS, 2019-2025
30 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,521 · 2020: $2,509 · 2021: $2,034 · 2022: $656 · 2023: $760 · 2024: $754 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,978.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,370.09 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,128.85 | 2021-2025 | |
| Amgen INC. | $1,124.70 | 2019-2023 | Repatha, Otezla |
| Novo Nordisk INC | $770.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $720.92 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $563.95 | 2019-2024 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $507.58 | 2019-2021 | |
| Allergan, INC. | $449.26 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $324.49 | 2019-2022 | |
| Lilly USA, LLC | $308.30 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.95 | 2020-2025 | Relistor |
| Sanofi-Aventis U.S. LLC | $261.94 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $246.09 | 2019-2021 | |
| Abbott Laboratories | $123.87 | 2022-2023 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $92.26 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $70.00 | 2021 | |
| Medicure Pharma INC. | $49.95 | 2020 | |
| Indivior INC. | $49.09 | 2019 | |
| Pfizer INC. | $46.64 | 2019-2021 | |
| Horizon Therapeutics Plc | $35.53 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $32.40 | 2019 | |
| Boston Scientific Corporation | $27.64 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.29 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.17 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.85 | 2025 | |
| Snap Diagnostics LLC | $16.29 | 2021 | |
| Mannkind Corporation | $15.72 | 2019 | |
| Forte Bio-Pharma LLC | $14.78 | 2021 | |
| Hikma Pharmaceuticals USA | $13.35 | 2020 | |
| Spr Therapeutics, INC | $9.78 | 2025 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.